HIRAN ORGOCHEM LIMITED
Active pharmaceutical
ingredients
Hiran is the largest manufacturer of Ciprofloxacin with a 25-30 per cent market share and aims to attain global leadership in this product
segment. In fact the company is the number one producer of this
drug in the country with its products being exported to over 60
countries. Our constant endeavor to control costs and achieve
operational excellence has enabled the company to clock phenomenal
growth in this business. Going ahead, the focus of this business is to
move products from unregulated markets to regulated markets and optimise
the new products opportunities in regulated markets.
Manufacturing facilities
Hiran has successfully augmented its capacities more than 30 fold since
inception from 30 MT per annum to 960 MT per annum in 2005. The company
has two versatile manufacturing units in its plant at
Ankleshwar, Gujarat. Hiran ensures that the manufacturing capacities incorporate
best practices and adhere to stringent regulatory compliances and
quality norms. Further, our state-of-the-art manufacturing facilities have reactors
with an existing capacity of 251,620 litres. These reactors can handle
temperatures from 0-1500C and maintain pressure up to 5kg/cm2 and the
reactions preformed and can be performed are as follows:
Formulations
Hiran commenced operations primarily as an API bulk drug manufacturer,
but in order to lure attractive margins and increase its realisations
Hiran intends to move up the value chain by a foray into the
formulations space through contract manufacturing. Thus, as a forward
integration initiative to manufacture Ciprofloxacin Formulation,
the company commissioned a new division - Hiran Lifesciences for formulations. This division would
manufacture different formulations, which will address the requirements of
pharmaceutical companies globally.
Reactions performed
Reactions can be performed
Currently, the company is engaged in formulations through contract
manufacturing but going ahead it intends to establish its own
manufacturing unit in Gujarat along with a US FDA approved unit. This
new unit would be well equipped with R&D as Hiran views its R&D
capabilities as a vital component of its business strategy that will
provide the company a sustainable, long-term competitive advantage. At
Hiran, research meets technology everyday and experience & equipment
come together in a winning combination to deliver solutions that match
international standards.
QUALITY
Quality is always the result of sincere efforts, intelligent direction
and skillful execution. To be competitive, Hiran fully appreciates that
it needs to provide a product, into which quality is designed, built and
consistently maintained at the most economical costs. Hiran possesses
GMP compliance and follows ICH guidelines with regards to quality at its
multi-functional API manufacturing facility, which helps optimise
production costs with speed and accuracy. At Hiran, the quality team
begins to contribute to the product right from the development stage and
to ensure quality control, at every stage Hiran has put in place a well
-equipped quality control department responsible for a detailed quality
check of each and every batch thereby ensuring that the customer
receives product of the highest quality.
FUTURE
Pharmaceuticals companies' across the glob are today injecting a new
dose of competitiveness by focusing on building world-class and
intellectually driven organisations to compete in the markets of the
future. Hiran has the vision to emerge as a knowledge-based and
dependable pharmaceutical supplier to the global healthcare industry and
in out endeavor to do so we have embarked on developing an ecommerce
site. This would enable us to expand our market base and will narrow
down our distribution chain and network. To move to the next stellar level and attain global leadership, in
addition to expanding capacities, launching new products and embarking
on backward integration, Hiran has forayed into the manufacture of
formulations which will cumulatively sharpen its edge in cost-effective,
quality and end-to-end solutions in the quinolones group of products
enabling it to emerge as one complete integrated player.
Product List
| HUMAN
API'S |
|
|
|
| ANTI
BACTERIAL'S |
ANTI
MALARIAL |
API'S
UNDER DEVELOPMENT |
|
|
|
|
|
Ciprofloxacin
HCL
Ciprofloxacin Base
Ciprofloxacin Lactate
Ofloxacin
Levofloxacin Hemihydrate |
QuinneSulphate
QuinneBsulphate
QuinneHCL
Quinnedi
HCL
|
Azithromycin
Clarithromycin
Omeprazole
Pantoprazole Sodium
Levocetirizine
Danofloxacin Mesylate |
Fluconazole
Losartan
Potassium
Atorvastatin
Simvastatin
Sildenafil
Citrate |
| VETERINARY
APIS |
|
|
|
|
|
|
|
Enrofloxacin HCL
Enrofloxacin Base
Enrofloxacin Lactate
Difloxacin HCL
Difloxacin Base |
Difloxacin Lactate
Sarafloxacin HCL
Sarafloxacin Base
Sarafloxacin Lactate |
|
|
|
|
